S1K Stock Overview
A knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of optimal cancer therapies.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Predictive Oncology Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.03 |
| 52 Week High | US$5.95 |
| 52 Week Low | US$0.99 |
| Beta | 1.33 |
| 11 Month Change | -40.46% |
| 3 Month Change | -46.35% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -58.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| S1K | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 4.0% | -0.2% | -0.5% |
| 1Y | n/a | -0.1% | 1.6% |
Return vs Industry: Insufficient data to determine how S1K performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how S1K performed against the German Market.
Price Volatility
| S1K volatility | |
|---|---|
| S1K Average Weekly Movement | 18.3% |
| Medical Equipment Industry Average Movement | 4.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: S1K's share price has been volatile over the past 3 months.
Volatility Over Time: S1K's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 35 | Raymond Vennare | www.predictive-oncology.com |
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of optimal cancer therapies. It operates through three segments: Pittsburgh, Birmingham, and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of approximately 150,000 tumor samples and creates proprietary 3D culture models used in drug development.
Predictive Oncology Inc. Fundamentals Summary
| S1K fundamental statistics | |
|---|---|
| Market cap | €3.93m |
| Earnings (TTM) | -€13.76m |
| Revenue (TTM) | €1.82m |
2.1x
P/S Ratio-0.3x
P/E RatioIs S1K overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| S1K income statement (TTM) | |
|---|---|
| Revenue | US$1.96m |
| Cost of Revenue | US$702.07k |
| Gross Profit | US$1.26m |
| Other Expenses | US$16.04m |
| Earnings | -US$14.78m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.60 |
| Gross Margin | 64.18% |
| Net Profit Margin | -754.19% |
| Debt/Equity Ratio | 0.9% |
How did S1K perform over the long term?
See historical performance and comparison